A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

Investigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival (PFS) in advanced-stage head and neck squamous cell carcinoma (HNSCC) and provide outcomes related to correlative biological factors associated with disease control. This was a prospective, randomized, dou...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-12, Vol.28 (23), p.5040-5048
Hauptverfasser:	Nathan, Cherie-Ann O, Hayes, D Neil, Karrison, Theodore, Harismendy, Olivier, Flores, José M, Moore-Medlin, Tara, Vokes, Everett E, Gutkind, J Silvio, Neupane, Prakash, Mills, Glenn, Sargi, Zoukaa, Seiwert, Tanguy, Grilley-Olson, Juneko, Day, Terry, Gillison, Maura, Wade, James L, Feldman, Lawrence, Jha, Gautam, Kozloff, Mark, O'Leary, Miriam, Worden, Francis P, Cohen, Ezra E W
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - genetics Epithelial Cells - pathology Everolimus - adverse effects Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics Humans Male Middle Aged Prospective Studies Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!